Affiliation:
1. School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
2. Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia
Abstract
The development and approval of antivirals against SARS-CoV-2 has further equipped clinicians with treatment strategies against the COVID-19 pandemic, reducing deaths post-infection. Extensive clinical use of antivirals, however, can impart additional selective pressure, leading to the emergence of antiviral resistance. While we have previously characterized possible effects of circulating SARS-CoV-2 missense mutations on proteome function and stability, their direct effects on the novel antivirals remains unexplored. To address this, we have computationally calculated the consequences of mutations in the antiviral targets: RNA-dependent RNA polymerase and main protease, on target stability and interactions with their antiviral, nucleic acids, and other proteins. By analyzing circulating variants prior to antiviral approval, this work highlighted the inherent resistance potential of different genome regions. Namely, within the main protease binding site, missense mutations imparted a lower fitness cost, while the opposite was noted for the RNA-dependent RNA polymerase binding site. This suggests that resistance to nirmatrelvir/ritonavir combination treatment is more likely to occur and proliferate than that to molnupiravir. These insights are crucial both clinically in drug stewardship, and preclinically in the identification of less mutable targets for novel therapeutic design.
Funder
National Health and Medical Research Council
Victorian Government’s Operational Infrastructure Support Program
Subject
Genetics (clinical),Genetics
Reference46 articles.
1. Coronavirus biology and replication: Implications for SARS-CoV-2;Kratzel;Nat. Rev. Microbiol.,2021
2. WHO Declares COVID-19 a Pandemic;Cucinotta;Acta Biomed.,2020
3. An interactive web-based dashboard to track COVID-19 in real time;Dong;Lancet Infect. Dis.,2020
4. Next-generation vaccine platforms for COVID-19;Nat. Mater.,2020
5. Kumar, S., Chandele, A., and Sharma, A. (2021). Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLoS Pathog., 17.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献